Neurocrine halts development of schizophrenia drug as trial fails
Sept 12 (Reuters) – Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not achieve the primary goal in a mid-stage trial. If you cherished this article and also you would like to get more info relating to…